ELK4 Promotes Colorectal Cancer Progression by Activating the Neoangiogenic Factor LRG1 in a Noncanonical SP1/3‐Dependent Manner

Although the MAPK/MEK/ERK pathway is prevalently activated in colorectal cancer (CRC), MEK/ERK inhibitors show limited efficiency in clinic. As a downstream target of MAPK, ELK4 is thought to work primarily by forming a complex with SRF. Whether ELK4 can serve as a potential therapeutic target is un...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhehui, Guo, Yuegui, Liu, Yun, Ding, Rui, Huang, Zhenyu, Yu, Wei, Cui, Long, Du, Peng, Goel, Ajay, Liu, Chen‐Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646254/
https://www.ncbi.nlm.nih.gov/pubmed/37786278
http://dx.doi.org/10.1002/advs.202303378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646254/
https://www.ncbi.nlm.nih.gov/pubmed/37786278
http://dx.doi.org/10.1002/advs.202303378

Ejemplares similares